companies
invested in
Founders backed by entrepreneurs
We are one of the most active venture capital family offices in Europe. Founded by two serial entrepreneurs, investing in tech start-ups in early stages mainly in the US, UK, Baltic region and Central Europe.
Read our storymillion β¬ of
private money
dedicated
countries
invested in
exits
cities our startups
operate in
Portfolio
Portfolio
Portfolio
There's already 50 companies on all 5 continents that we believe in
United States
Improving human lifespan by targeting dysfunctional *LI*pid *ME*tabolism
Czech Republic
SharpGrid provides vendors with insights and transparency about the on-trade / out-of-home channel.
United States
Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate.
Spain
We bring any service (cleaning, beauty, dog grooming…) to your doorstep
United States
Combinatorial therapeutics for the world's toughest diseases
Croatia
SpectreXR is on a mission to change the way how people interact in virtual and augmented reality.
Estonia
Get the medical help you need. Anytime, anywhere. Fast & affordable alternative to a family doctor.
United States
Get direct science-based answers to medical questions at medisearch.io.
United States
Programmable delivery of mRNA medicines
United States
Solving fundamental problems in drug discovery to create a new generation of therapeutics.
Tripmakery / bit.bio / Alpha3D / Supliful / Miros / Sensible Biotechnologies / Deskree / CRUXO / e-mobilio / Prograd / Wectory / Flexkeeping /
Velaris / Stackt / Orderlion / Talkie.ai / Swarm Analytics / StoryBox / memtime / Startup Wise Guys / Spiritus / Sorwe / smino / ZeePrime /
SaaShop / Rendin / Readmio / Positive Carbon / Fyrfeed / Blockmate / We Make Games / CorpLife / Conntac / boam / easySales / GitGut /
News
04/11/2024
Congrats to Miroslav and Marian from Sensible Biotechnologies for being selected for Forbes 30u30 Europe in the Science & Healthcare category π π π
04/08/2024
ZAKA VC invests in Lime Therapeutics, unlocking a new class of lipid-targeting medicines
03/20/2024